Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on LinkedIn:
“HER2-mutant NSCLC has carried a poor prognosis with limited options. A US clinico-genomic study in Lung Cancer sets a real-world baseline from before any US HER2 TKI approval.
158 patients started first-line therapy for advanced HER2-mutant NSCLC, January 2015 to March 2024 (43.0% YVMA):
- Median rwPFS/OS 5.7/17.5 months from 1L; 4.3/11.2 months from 2L
- 1L was mostly chemo + ICI (36.1%) or chemo (27.8%); HER2-targeted ADC was 16.3% of 2L
- Outcomes appeared descriptively worse with YVMA
This is the bar HER2-targeted therapy has to beat in practice. For me it starts with upfront NGS, so the HER2 mutation is known before first-line treatment.
Several authors are Bayer employees, per the disclosures.
What should a post-TKI real-world cohort measure first?”
Title: Characteristics and outcomes of patients with advanced or metastatic non–small cell lung cancer harboring a HER2-activating mutation: a real-world retrospective cohort study using a US clinico-genomic database
Authors: Xiuning Le, Christos Chouaid, Fernando Lopez-Rios, Mei Sheng Du, Maral DerSarkissian, Vadim Bernard-Gauthier, Jihong Zong, Zdravko Vassilev, Orsolya Lunacsek, Angela Lax, Andreas Schlicker, Rose Chang, Megan Pinaire, Naiyu Chen, Qayyim Said.
You can also read:
Japan Approves Zongertinib for First-Line Treatment of HER2-Mutant Advanced NSCLC
